IGF-1 LR3 research peptide
An analogue of insulin-like growth factor I with an N-terminal extension and arginine at residue 3, designed to bind IGF-binding proteins poorly.
Sizes, prices and availability
| Size | SKU | Stated purity | Batch COA | Price | Availability | |
|---|---|---|---|---|---|---|
| 0.1 mg | IG01 | Not yet provided | Not yet provided | $14.99 | Out of stock | |
| 1 mg | PP-IGF1LR3-1MG | Not yet provided | Not yet provided | $43.99 | In stock |
Prices and stock are checked at build time and refreshed live in your browser. Orders are US only for a flat $24.95 shipping fee. Shipping details
About IGF-1 LR3
IGF-1 LR3 (long R3 IGF-I, LR3IGF-I) is an analogue of human insulin-like growth factor I (IGF-I). Tomas et al. (1992) describe it as a variant with an N-terminal extension as well as arginine at residue 3, and as an analogue that binds poorly to IGF-binding proteins (IGFBPs); the same paper reports that it binds about 3-fold less well than IGF-I to the type 1 IGF receptor.
Because it binds IGFBPs poorly, LR3IGF-I behaves differently from IGF-I in animal studies. Bastian et al. (1993) report, in rats, that it was cleared from plasma more rapidly than IGF-I, that most of it was detected as free peptide, and that more of the labelled analogue than of IGF-I was found in kidneys, ovaries and adrenals. Tomas et al. (1992) report that in dexamethasone-treated rats IGF-I variants were about 2.5-fold more potent than IGF-I in an anabolic model, and Tomas (2001) reports a 7-day food-restriction study in young and adult rats in which infused LR3IGF-I maintained body weight and nitrogen retention but did not conserve muscle protein. Pampusch et al. (2005) used Long-R3-IGF-I in porcine myoblast cultures as an IGF analogue with very low affinity for IGFBPs, to separate IGF-dependent from IGF-independent effects of IGFBP-5. The work above is in rats and cell culture.
What the published literature covers
- Tomas et al. (1992) compare IGF-I, des(1-3)IGF-I and LR3IGF-I in dexamethasone-treated rats.
- Bastian et al. (1993) report plasma clearance and tissue distribution of labelled IGF-I and LR3IGF-I in pregnant and virgin rats.
- Tomas (2001) reports LR3IGF-I infusion during food restriction in young and adult rats.
- Pampusch et al. (2005) use Long-R3-IGF-I as an IGFBP-insensitive IGF analogue in porcine embryonic myoblast cultures.
Vial arithmetic
The peptide reconstitution calculator converts a vial size, diluent volume and target amount into concentration, syringe units and draws per vial. Volumes convert to syringe units with the syringe units converter. It does arithmetic only and does not suggest any amount.
FAQ
What is IGF-1 LR3?
An analogue of insulin-like growth factor I with an N-terminal extension and arginine at residue 3, which reduces its binding to IGF-binding proteins (Tomas et al., 1992).
How does it differ from native IGF-I?
Native IGF-I is a 70-residue chain with three disulfide bonds (UniProt P05019). LR3IGF-I carries an N-terminal extension and Arg at residue 3, so it is larger, and it binds IGFBPs poorly.
What identity check should a batch have?
Mass spectrometry. The native IGF-I mass is about 7648.7 g/mol (computed from the sequence); the LR3 analogue is heavier, so read the COA mass against the supplier's stated sequence.
What sizes of IGF-1 LR3 does Covalume list?
Covalume lists IGF-1 LR3 in 2 sizes: 0.1 mg, 1 mg. Each size shows its price and live stock status in the variants table on this page.
How is the purity of IGF-1 LR3 documented?
Each listing shows the purity the supplier states, labelled (supplier), and the batch Certificate of Analysis field reads "Not yet provided" until a batch-specific document is on file. Our guide to reading a Certificate of Analysis explains what HPLC and mass-spectrometry results show.
References
- Tomas FM, Knowles SE, Owens PC, et al. (1992). Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J 282 ( Pt 1):91-7. PubMed 1371669 · DOI
- Bastian SE, Walton PE, Wallace JC, et al. (1993). Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. J Endocrinol 138:327-36. PubMed 7693845 · DOI
- Tomas FM (2001). Insulin-like growth factor-I (IGF-I) analogue, LR(3)IGF-I, ameliorates the loss of body weight but not of skeletal muscle during food restriction. Growth Horm IGF Res 11:92-103. PubMed 11472075 · DOI
- Pampusch MS, Xi G, Kamanga-Sollo E, et al. (2005). Production of recombinant porcine IGF-binding protein-5 and its effect on proliferation of porcine embryonic myoblast cultures in the presence and absence of IGF-I and Long-R3-IGF-I. J Endocrinol 185:197-206. PubMed 15817840 · DOI
Identity values are from PubChem and the cited papers; for linear peptides the mass was also checked against the sequence. Last updated 2026-11-19.
Related research peptides
- Tesamorelin Growth-hormone-releasing factor (GHRH) analogue
- Sermorelin GHRH(1-29) amide analogue
- Ipamorelin Pentapeptide growth hormone secretagogue
- CJC-1295 Long-acting GHRH analogue
- All growth-hormone axis peptides
From the research library
- Check the mass spectrometry on a COA yourself
- Peptide degradation pathways
- Peptide reconstitution: concentration and volume math
- Peptide purity vs peptide content: a vial mass balance
- How to read a COA HPLC chromatogram
- HPLC vs LC-MS for peptides: identity and purity workflow
- How to read an LC-MS trace: a worked peptide example
- TFA to acetate: peptide counter-ion exchange
- Peptide net charge, pI and solubility by pH
- Peptide adsorption to vials and plastics
- How long do peptides last? Stability evidence explained
- Bacteriostatic water vs sterile water